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Summary
 
Factor H (fH), a key alternative complement pathway regulator, is a cofactor for factor I–medi-
ated cleavage of C3b. fH consists of 20 short consensus repeat (SCR) domains. Sialic acid bind-
ing domains have previously been localized to fH SCRs 6–10 and 13. To examine fH binding
on a sialylated microbial surface, we grew 
 
Neisseria gonorrhoeae
 
 in the presence of 5
 
9
 
-cyti-
dinemonophospho-
 
N
 
-acetylneuraminic acid, which sialylates lipooligosaccharide and converts
to serum resistance gonococci previously sensitive to nonimmune serum killing. fH domains
necessary for binding sialylated gonococci were determined by incubating organisms with re-
combinant human fH (rH) and nine mutant rH molecules (deletions spanning the entire fH
molecule). rH and all mutant rH molecules that contained SCRs 16–20 bound to the sialylated
strain; no mutant molecule bound to serum-sensitive nonsialylated organisms. Sialic acid was
demonstrated to be the fH target by flow cytometry that showed a fourfold increase in fH
binding that was reversed by neuraminidase-mediated cleavage of sialic acid off gonococci.
Functional specificity of fH was confirmed by decreased total C3 binding and almost complete
conversion to iC3b on sialylated gonococci. Sialic acid can therefore bind fH uniquely through
SCRs 16–20. This blocks complement pathway activation for 
 
N. gonorrhoeae
 
 at the level of C3.
 
F
 
actor H (fH)
 
1
 
 is a critical regulator of the complement
system, and acts as a cofactor for factor I–mediated
cleavage of C3b (1–3). fH also inactivates alternative path-
way convertase by dissociating Bb from the C3b,Bb com-
plex (3–5). fH is a 150-kD single-chain glycoprotein com-
posed entirely of 20 short consensus repeat (SCR) domains
(6), each comprising 60 amino acid residues. Each SCR is
characterized by four highly invariant cysteine residues and
by many highly conserved amino acids folded into compact
units. Three regions on fH are capable of binding C3b:
SCRs 1–5, which bear the cofactor activity; SCRs 6–10;
and SCRs 16–20 (7). fH has the ability to bind polyanions
such as sialic acid, heparin, and most sulfated glycosami-
noglycans (8). Heparin binding sites have been shown pre-
viously to reside in SCR 13 (9) and in a region spanned by
SCRs 6–10 (7, 10). Sialic acid–containing surfaces enhance
the interaction between C3b and fH (11, 12). fH binding
proteins that may contribute to pathogenicity by inhibiting
complement-mediated destruction have been identified on
several microbes. These include the streptococcal M6 pro-
tein (13, 14), the Yad A protein of 
 
Yersinia enterocolitica
 
 (15),
and glycoproteins (gp) 120 and 41 120 of HIV-1 (16–20).
Gonorrhea remains one of the major sexually transmitted
diseases worldwide. 
 
Neisseria gonorrhoeae
 
 causes a wide spec-
trum of disease including asymptomatic infection, urethri-
tis, cervicitis, pelvic inflammatory disease, and disseminated
gonococcal infection. Gonococcal strains may be classified
as serum sensitive (SS) or serum resistant (SR), depending
on their susceptibility to killing by normal human serum
(NHS; reference 21). SS strains predominantly result in
symptomatic local inflammation, whereas SR strains may
cause disseminated infection in the absence of substantial
local genital symptoms (22–24).
The mechanisms employed by SS strains to evade host
defenses are not fully understood. Gonococci initially re-
covered from urethral exudates and directly tested without
subculture resist the bactericidal activity of NHS, but lose
this ability after serial subcultures in vitro (25). A series of
elegant and detailed studies by Smith and coworkers
showed that incubation and growth of gonococci in hu-
man fluids and secretions resulted in the conversion of SS
gonococci to SR gonococci (26–28). A low–molecular
weight dialyzable substance present in human sera (26, 27),
 
1
 
Abbreviations used in this paper:
 
 CMP-NANA, 5
 
9
 
-cytidinemonophospho-
 
N
 
-acetylneuraminic acid; fH, factor H; HIS, heat-inactivated serum;
LOS, lipooligosaccharide; NHS, normal human serum; rH, recombinant
fH; SCR, short consensus repeat; SR, serum-resistant; SS, serum-sensi-
tive.
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leukocytes (29), erythrocytes (30–33), and guinea pig sera
(30, 33, 34) renders the organism resistant to the direct kill-
ing action of NHS. This substance has been identified as
the nucleotide sugar for sialic acid, 5
 
9
 
-cytidinemonophos-
pho-
 
N
 
-acetylneuraminic acid (CMP-NANA). Purified CMP-
NANA added to gonococcal growth media in nanogram
amounts duplicates all of the effects of the low M
 
r
 
 factor
with gonococci (33), including an increase in the molecular
weight of their lipooligosaccharide (LOS; reference 31)
that corresponds to the addition of a sialic acid residue to
the LOS molecule. No concomitant alteration of any of
the gonococcal outer membrane proteins has been ob-
served (29). The acceptor site on LOS for sialic acid has
been determined to be the terminal galactose of the lacto-
neoseries LOS structure (31, 35, 36) (Gal
 
b
 
1
 
®
 
4GlcNAc)
that is antigenically identical to certain human glycolipids
(37). The sialylation epitope is recognized by mAb 3F11,
whose binding to gonococci is diminished when strains are
grown in the presence of CMP-NANA. Binding is re-
stored on neuraminidase treatment of the bacteria (36),
which cleaves off sialic acid but otherwise leaves the organ-
ism intact. This effect also occurs in vivo, because gono-
cocci from male urethral exudates fail to bind mAb 6B4,
which also recognizes the sialylation epitope specifically on
LOS. Again, binding is restored by neuraminidase treat-
ment of the cells in situ (38). Electron microscopic exami-
nation of gonococci directly in urethral exudates shows a
surface structure stained by ruthenium red that disappears
on neuraminidase treatment (39, 40). Collectively, these
data provide evidence for in vivo sialylation of gonococcal
LOS. Although the gonococcal lipooligosaccharide 
 
a
 
-2,3-
sialyltransferase gene has been cloned and expressed (41),
some gonococcal strains that are serum resistant do not express
the Gal
 
b
 
1
 
®
 
4GlcNAc LOS acceptor site and therefore can-
not be sialylated. The mechanism of this stable serum resis-
tance is not fully understood.
Sialic acid is used as a virulence factor by several micro-
organisms. Capsular sialic acid of type III, group B strepto-
cocci prevents activation of the alternative complement
pathway (42). The ability of the Sindbis virus to activate
the alternative pathway of complement is inversely related
to its host-determined envelope sialic acid content (43),
which in turn is dependent on host tissue sialic acid content
(44). Trypomastigotes of 
 
Trypanosoma cruzi
 
 express an un-
usual cell-surface trans-sialidase that enables the parasite to
rapidly sialylate its surface when supplied with 
 
a
 
(2
 
®
 
3)-
linked sialic acid in the form of glycoconjugates in serum or
on cell surfaces. Desialylation of the trypomastigotes results
in an increased ratio of C3b to the inactive molecule, iC3b,
and results in increased lysis of the organism (45). A study
of the bactericidal activity of the alternative complement
pathway of the channel catfish (
 
Ictalurus punctatus
 
) against 15
gram-negative fish pathogens and nonpathogens found a
strong correlation between the presence of sialic acid on
the pathogenic strains and the absence of bactericidal activ-
ity against these strains, whereas the highly susceptible non-
pathogenic strains lacked sialic acid (46).
In this study we demonstrate that sialylated gonococci
bind more fH than do their nonsialylated counterparts.
This is the first clear demonstration of fH binding to sialic
acid on a microbial surface and occurs through a novel
sialic acid binding site on fH that was not predicted by pre-
vious in vitro experiments. This results in increased con-
version of bound C3b to iC3b on the organism, which
may be a mechanism for their serum resistance in vivo.
 
Materials and Methods
 
Bacterial Strains and Growth of Organisms. N. gonorrhoeae
 
 strain
24-1, an SS strain (47) isolated from a patient with pelvic inflam-
matory disease, was used in this study. Gonococci were first
grown for 13 h overnight on solid media in 5% CO
 
2
 
 at 37
 
8
 
C and
then inoculated into standard gonococci liquid media and grown
to mid-log phase (48).
 
fH and Recombinant fH Deletion Mutants.
 
Human complement
fH was purified from human plasma to a final concentration of
1 mg/ml in PBS (1). Recombinant fH (rH) and nine rH deletion
mutant molecules were generated by overlap extension PCR, ex-
pressed in insect cells using the baculovirus system, and then puri-
fied by immunoaffinity chromatography (7, 49; see below). The
rH molecule possesses equivalent cofactor activity to native fH
purified from human plasma (49). Deletions in the nine rH mu-
tant molecules span the entire length of the fH molecule and are
shown in Fig. 1.
 
Sera.
 
Pooled NHS was obtained from 11 healthy volunteers
with no prior history of gonococcal infection. Heat-inactivated
serum (HIS) was prepared by incubating NHS at 56
 
8
 
C for 30 min.
 
CMP-NANA and Neuraminidase Treatment.
 
To achieve max-
imum sialylation of gonococci, 80 
 
m
 
g of CMP-NANA was added
(Boehringer-Mannheim Biochemicals, Indianapolis, IN) per ml
of liquid media. In some experiments, CMP-NANA–treated or-
ganisms were treated with neuraminidase (Type V; Sigma Chem-
ical Co., St. Louis, MO) reconstituted in 100 mM NaCl, 50 mM
NaOAc, 5 mM CaCl
 
2
 
, and 5 mM MgCl
 
2
 
, pH 6.0 (neuraminidase
buffer) to a concentration of 10 U/ml. 1.5 U of neuraminidase
was added to 2 
 
3
 
 10
 
8
 
 cells (final concentration: 6 U/ml in the in-
cubation system) and incubated for 1 h at 37
 
8
 
C.
 
mAbs.
 
mAbs C-5G and C-3E directed against human C3b
and iC3b, respectively (reference 50; gift of Dr. Kyoko Iida,
Takeda Chemical Industries, Ltd., Tsukuba, Japan), were used in
whole cell ELISAs (see below) to monitor these complement
components bound to gonococcal strains. mAb specific for the Bb
neoantigen fragment of factor B (reference 51; Quidel, San Di-
ego, CA) was used to detect alternative pathway convertase
(C3b,Bb) on the organisms. mAb 2C3, which binds the H.8 lipo-
protein antigen (38) present on all pathogenic gonococcal strains
(52), was used to monitor the number of organisms deposited in
each well. All mAbs in ELISAs were used at a concentration of
25 
 
m
 
g/ml. mAb 3F11 (gift of Dr. Michael A. Apicella, University
of Iowa, Iowa City, IA) specifically binds the nonsialylated
Gal
 
b
 
1
 
®
 
4GlcNAc epitope on gonococcal LOS (53) and was used
in Western blotting experiments (final concentration: 10 
 
m
 
g/ml)
to monitor the effects of neuraminidase treatment upon sialylated
gonococci. Sialylation of LOS results in loss of 3F11 binding,
which is restored after neuraminidase treatment (36).
 
Flow Cytometry.
 
We used flow cytometry to quantitate bind-
ing of fH and recombinant mutant factor H molecules to gono-
cocci. Each sample tube contained 2 
 
3
 
 10
 
8
 
 bacteria recovered
from liquid culture, which had been washed twice in HBSS
(Sigma Chemical Co.) at room temperature and then resus- 
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pended in HBSS. All buffers were passed through a 0.22-
 
m
 
m fil-
ter (Millipore Corporation, Bedford, MA) to exclude particles
that could interfere with flow cytometry. The bacterial suspen-
sion (90 
 
m
 
l) was incubated for 10 or 30 min at 37
 
8
 
C with 10 
 
m
 
l
NHS, or 10 
 
m
 
l HIS, or 5 
 
m
 
g purified fH (1 mg/ml in PBS). Sus-
pensions were centrifuged at 10,000 
 
g
 
 for 2 min and pellets were
washed once with HBSS before adding anti-fH antibody used for
detecting fH (see below).
To demonstrate that the sialic acid residue on LOS was the ac-
ceptor molecule for fH, we treated organisms with neuraminidase
after they had been incubated with fH. Sialylated organisms (2 
 
3
 
10
 
8
 
) recovered from liquid culture were resuspended in 100 
 
m
 
l of
neuraminidase buffer, and then 5 
 
m
 
g of purified human fH was
added. The mixture was incubated for 30 min at 37
 
8
 
C, then 1.5
U of type V neuraminidase, or neuraminidase buffer alone (posi-
tive control) was added, followed by incubation for 1 h at 37
 
8
 
C.
24-1 NANA treated with neuraminidase before the addition of
fH (neuraminidase was removed by washing, ensuring that fH
was not desialylated) and 24-1 treated with fH alone were used as
the negative controls.
Surface-bound fH was monitored by the addition of affinity-
purified polyclonal rabbit anti-fH (final dilution of 1:100 of a 0.26
mg/ml stock solution) for 30 min at room temperature, followed
by FITC-labeled anti–rabbit IgG (Sigma Chemical Co.; final di-
lution of 1:100). The bacteria were resuspended in 1 ml HBSS
and applied to a fluorescence-activated cell sorter (FACScan
 
Ò
 
,
Becton Dickinson Immunocytometry Systems, San Jose, CA) and
50,000 events were counted.
The region of fH responsible for binding to sialylated gono-
coccal LOS was determined by incubating 2.5 
 
m
 
g of each of the
fH mutant molecules with gonococci, followed by detection with
rabbit anti-fH as described above. All recombinant proteins were
purified from the medium supernatant by application to an anti-
fH–Sepharose immunoadsorbent column using the same anti-fH
reagent (7, 49). This confirmed that the anti-fH antibody used in
these experiments bound all of the rH mutant proteins.
 
Western Blots.
 
fH binding to gonococci after incubation with
serum or purified fH was also detected by Western blotting. After
gonococci were harvested and washed, 4 
 
3
 
 10
 
8
 
 cells suspended in
180 
 
m
 
l of HBSS were opsonized with 20 
 
m
 
l of serum or 10 
 
m
 
g of
purified fH for 30 min at 37
 
8
 
C. 180 
 
m
 
l of the organism-contain-
ing mixtures were then layered onto 20% sucrose in HBSS and
centrifuged at 10,000 
 
g
 
 for 3 min to separate free fH from that
bound to organisms. The pellets were harvested, resuspended in
35 
 
m
 
l of 1% SDS, and boiled for 30 min. After centrifugation
(10,000 
 
g
 
 for 10 min), 25 
 
m
 
l of the supernatant was carefully pi-
petted out, and protein concentration was determined by the
bicinchonic acid assay (BCA assay kit; Pierce Chemical Co.,
Rockford, IL). Samples containing equal amounts of protein
were digested (0.3 M Tris HCl [pH 6.8], 2% SDS, 12.5% glyc-
erol), boiled for 5 min, separated by 10% SDS-PAGE, and trans-
ferred onto an Immobilin PVDF transfer membrane (Millipore;
reference 54). Nonspecific binding sites were blocked with 1%
(wt/vol) natural nonfat dry milk in PBS. Western blots were then
incubated with polyclonal sheep anti–human fH (The Binding
Site, Birmingham, UK; final dilution: 1:1000) in PBS containing
1% BSA for 1 h at room temperature. Specificity of binding was
identified with alkaline phosphatase–conjugated anti–sheep IgG
antibody (Sigma Chemical Co.), and visualized after the addition
of substrate (55).
 
ELISA.
 
We measured C3b, iC3b, factor Bb, and C3 binding
to gonococci opsonized with NHS by ELISA. 2 
 
3
 
 10
 
8
 
 organisms
were incubated with 10 
 
m
 
l NHS (10 min at 37
 
8
 
C) as described
for flow cytometry. Reactions were stopped after 10 min by
washing three times with ice cold HBSS containing 5 mM PMSF
(Calbiochem Corp., La Jolla, CA) in a refrigerated microcentri-
fuge (National Labnet Co., Woodbridge, NJ). Organisms were
resuspended in 200 
 
m
 
l of the same buffer, and 50 
 
m
 
l of each sam-
ple was applied per well of a 96-well U-bottomed polystyrene
microtiter plate (Dynatech Laboratories, Inc., Chantilly, VA) for
3 h at 37
 
8
 
C. The plates were washed with PBS containing 0.05%
Tween 20. Primary antibodies were diluted in PBS, and second-
ary antibodies were diluted in PBS/0.05% Tween 20. Total C3
bound to organisms was detected using polyclonal goat IgG frac-
tion to human complement C3 (Organon Teknika-Cappel,
Durham, NC; final concentration of specific antibody: 7 
 
m
 
g/ml)
followed by anti–goat IgG alkaline phosphate conjugate (Sigma
Chemical Co.). C3b, iC3b and factor Bb bound to organisms
were separately measured by mAbs directed against these compo-
nents, followed by anti–mouse IgG alkaline phosphatase conju-
gate (Sigma Chemical Co.). To normalize the measurement of
complement components per unit of organism, we determined
H.8 gonococcal antigen concentration coated to wells as a mea-
sure of gonococcal density using mAb 2C3 (38), followed by
anti–mouse IgG alkaline phosphatase conjugate.
 
Results
 
Binding of fH to Gonococci.
 
Direct binding of fH to 24-1
and 24-1 NANA was demonstrated by incubation under
three conditions: in NHS, HIS, or pure fH. Flow cytomet-
ric analysis of fH binding to 24-1 and its sialylated deriva-
tive (24-1 NANA) demonstrated significantly (fourfold)
greater deposition of fH on 24-1 NANA when incubated
with NHS. Results are shown for a 30 min incubation pe-
riod in NHS to allow for maximal shedding of C3b-bound
fH by sensitive 24-1 gonococci (see below for results at 10
min of incubation), thereby permitting a better estimate of
the amount of fH binding directly to the organisms. The
difference in fH binding was even more pronounced in the
Figure 1. Schematic representation of rH and the nine deletion mutant
molecules used in this study. Each circle represents an individual SCR. rH
and rH constructs lacking the indicated domains were generated by PCR,
expressed in insect cells using the baculovirus system, and purified for use
in this study (7, 49). 
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absence of intervening C3b when the organisms were in-
cubated with HIS or pure fH. Here, 24-1 showed no sig-
nificant binding of fH directly. Fig. 2 depicts one such ex-
periment representative of three replications. The specificity of
the binding of affinity-purified polyclonal rabbit anti-fH
was confirmed by incubating the bacteria with fH-depleted
serum, which yielded a reduction in the mean fluorescence
intensity to background isotype control levels (data not
shown).
fH binding on the surface of the two strains was also
studied by Western blotting (Fig. 3), which confirmed the
results obtained by flow cytometry. A visual comparison
was made by loading equal amounts (10 
 
m
 
g) of protein in
each lane. Again, 24-1 bound fH only when opsonized
with NHS, and the intensity of the band was qualitatively
less than the 24-1 NANA lanes.
 
C3 and iC3b Deposition on Gonococci.
 
To demonstrate the
functional consequences of fH binding, we quantitated
deposition of C3b (maximal at 10 min [data not shown]),
iC3b, factor Bb, and total C3 on the two strains (Fig. 4) us-
ing whole cell ELISAs. To normalize for the numbers of
organisms that were deposited in each well, we used mAb
2C3 to quantitate the amount of H.8 antigen present,
which showed an almost identical OD
 
410nm
 
 for both strains
(data not shown). To correlate the binding of C3 and its
components at 10 min of opsonization with fH binding,
we also measured fH binding at this time point by flow cy-
tometry. Similar to the results shown in Fig. 2 at 30 min,
there was no detectable binding of pure fH at 10 min.
However, at 10 min of opsonization in NHS, 24-1 bound
40% more fH, which by 30 min had diminished because of
loss of C3b-bound fH from the surface of the organism. fH
binding remained unchanged when 24-1 NANA was op-
sonized with NHS or pure fH at either time point.
Almost all the C3 on 24-1 NANA existed in the form of
iC3b. This was in sharp contrast to 24-1, where almost all
the C3 was in the form of C3b. The total C3 bound by 24-1
was fourfold greater than that by 24-1 NANA. Together
with the observation that factor Bb binding to 24-1 was
 
z
 
10-fold greater than that on 24-1 NANA, these findings
suggest that increased binding of fH to 24-1 NANA results
in highly efficient conversion of C3b to iC3b, and limits
total C3 deposition by inactivating the alternative pathway
C3 convertase (C3b,Bb).
 
Localization of the Site in fH that Binds to Sialylated Gono-
coccal Strain 24-1.
 
We determined the region of human
fH that bound to 24-1 NANA using rH and nine mutant
fH proteins lacking domains or groups of domains (Fig. 1).
The binding of rH and the nine mutant protein molecules
to 24-1 NANA were determined by flow cytometry using
affinity-purified polyclonal rabbit anti–human fH followed
by FITC-conjugated anti–rabbit IgG used as the detector
system. rH, in addition to all rH mutant molecules, except
rH
 
D
 
11-20 and rH
 
D
 
16-20, bound to 24-1 NANA (Fig. 5).
This suggests that SCRs 16–20 were essential for the bind-
ing of fH to 24-1 NANA. The experiment was repeated
using 1.25 
 
m
 
g of each of the mutant molecules, and similar
results were obtained. Neither rH nor any of the rH mu-
tants showed significant binding to 24-1 (histograms not
shown). Compared to intact rH, four of the rH mutant
Figure 2. Flow cytometric
quantitation of fH binding (using
affinity-purified polyclonal rabbit
anti–human fH) to sialylated
strain 24-1 NANA (top) and par-
ent strain 24-1 (bottom) when op-
sonized for 30 min with pooled
NHS (10 ml), HIS (10 ml), or
purified human fH (5 mg). 24-1
NANA showed significantly
greater fH binding under all
three conditions of opsonization.
Figure 3. Western blot con-
firming increased fH binding to
24-1 NANA compared to 24-1
(detected by sheep anti–human
fH), when incubated with NHS,
HIS, or purified fH.747 Ram et al.
protein molecules (rHD5, rHD13, rHD1-5, and rHD11-
15) showed more binding to 24-1 NANA (twofold or
greater as measured by median fluorescence intensity).
We attempted to inhibit the binding of purified human
fH to 24-1 NANA by preincubating fH with an excess of
heparin or N-acetylneuraminic acid (Type VI; Sigma Chemi-
cal Co.) at room temperature for 30 min, followed by the
addition of this mixture to the organisms. No decrease in
fH binding to the organism surface was seen by the flow
cytometry assay (data not shown). This provides further ev-
idence that a site distinct from the previously defined poly-
anion binding sites on fH is responsible for binding to 24-1
NANA.
Characterization of Sialic Acid as the Gonococcal Target for
fH. The role of sialic acid in the binding of fH was fur-
ther investigated by neuraminidase treatment of 24-1
NANA both before and after the organisms were incubated
with purified human fH. This was followed by flow cy-
tometry to detect fH bound to bacterial cells. Fig. 6 shows
that fH binding was reduced to near background levels in
both experiments. Neuraminidase treatment of 24-1 NANA
both before (Fig. 6 A) or after (Fig. 6 B) fH treatment re-
sulted in remarkably similar histogram plots.
The specificity of neuraminidase treatment on bacterial
cells was confirmed by SDS-PAGE electrophoresis and
Western blotting of the samples used for flow cytometric
analysis, followed by probing with mAb 3F11, which selec-
tively recognizes the sialylation site (in the unsialylated
state) on gonococcal LOS (Galb1®4 GlcNAc residue; ref-
erence 36). Sialylation of this LOS epitope results in loss of
3F11 binding, which is restored with neuraminidase treat-
ment. The 24-1 NANA sample that had been treated with
fH but not with neuraminidase showed a barely visible
band (Fig. 7, lane 1). In contrast, 3F11 reacted strongly
with the LOS of neuraminidase-treated samples (Fig. 7,
lanes  3 and 4).
Figure 4. Quantitation of C3b, iC3b, factor Bb, and total C3 binding
to 24-1 and 24-1 NANA after incubation in NHS for 10 min, deter-
mined by whole cell ELISA. Each bar represents the mean 6 SD of two
experiments. The ratio of C3b to iC3b binding was significantly greater
for 24-1 than 24-1 NANA, which bound almost no C3b. 24-1 NANA
bound z10-fold less Bb and 4-fold less total C3 than 24-1 (inset).
Figure 5. Binding of rH and
the nine rH mutant molecules to
24-1 NANA in a flow cytometry
assay. All molecules that con-
tained SCRs 16–20 bound to the
organism. Only rHD16-20 and
rHD11-20 did not show signifi-
cant binding, suggesting that
SCRs 16–20 are essential for fH
binding to 24-1 NANA.
Figure 6. Specificity of fH binding to sialic acid is shown by
neuraminidase treatment of 24-1 NANA both before (A, Neu®fH) and
after (B, fH®Neu) incubating the organisms with pure fH. In both ex-
periments, fH binding is reduced to near background levels. The solid
lines represent fH binding to 24-1 NANA (positive control), the shaded
areas represent fH binding to neuraminidase-treated samples, and the dot-
ted lines show isotype controls. No binding of fH above isotype control
levels was seen with 24-1 (data not shown).748 Novel Sialic Acid Binding Region in Factor H for Sialylated Gonococci
Discussion
Sialic acid is an essential component of eukaryotic cell
surfaces that plays an important role in preventing destruc-
tion of host tissue by constant low grade activation of the
alternative complement pathway. The affinity of C3b for
factor B remains constant on both activator and nonactiva-
tor surfaces; activator surfaces are characterized by a low
affinity of C3b for fH (56). Sialylation of eukaryotic mem-
brane surfaces enhances the interaction between C3b and
fH, resulting in highly efficient cleavage of C3b to iC3b
by factor I. Desialylation of red cell membranes results in
their conversion from nonactivators to activators of the al-
ternative complement pathway (12) as a result of a reduc-
tion in fH binding (57). Certain fluid-phase polyanions en-
hance binding of fH to C3b attached to activating surfaces,
which may be a mechanism of discrimination of host cells
and tissues from foreign cells that activate the alternative
pathway (58).
In vivo modification by sialylation of the terminal lacto-
syl residue in Neisseria gonorrhoeae (and other Neisseria spe-
cies) LOS is crucial in converting SS strains that possess
the Galb1®4GlcNAc epitope to an SR phenotype. A re-
cent study indicated that the sialylation of LOS and capsule
of N. meningitidis facilitates the formation of iC3b (59). Di-
rect binding of fH was proposed as the most likely explana-
tion but was not demonstrated, and organism-specific en-
dogenous complement-regulatory or fH-like activity, which
has been seen in other microorganisms, was not excluded
(60–67).
In our study, using flow cytometry as well as Western
blotting, we have shown that in vitro sialylation of gono-
coccal LOS by growth in the presence of CMP-NANA re-
sults in increased binding of fH. This in turn leads to highly
efficient conversion of C3b to iC3b, as evidenced by mini-
mal C3b deposition on 24-1 NANA (Fig. 4). In addition,
the total C3 detected on 24-1 NANA was significantly
(fourfold) less than on its nonsialylated variant because the
alternative pathway C3 convertase (C3b,Bb) had been in-
activated. This was confirmed by demonstrating a minimal
amount of factor Bb on 24-1 NANA, which limited the
accumulation of C3b on the surface of this strain. Fig. 2
shows minimal binding of fH to 24-1 when incubated with
NHS, but not with HIS or purified fH. This likely repre-
sents fH binding to the abundant amount of C3b deposited
on the organism. However, this limited degree of fH bind-
ing to C3b may not be functionally significant because very
little iC3b is detected on 24-1 (Fig. 4), and because 24-1 is
exquisitely sensitive to the bactericidal activity of nonim-
mune NHS (47).
fH binds sialic acid, heparin, and certain other polyan-
ions such as dextran sulfate, chondroitin sulfate A, and car-
rageenan (types III and IV). Little or no binding occurs
with chondroitin sulfate C, keratan sulfate, hyaluronic acid,
colominic acid (bacterial polysialic acid), or polyaspartic
acid (8, 9). These data demonstrate that the interaction be-
tween fH and polyanions is specific and in the case of sul-
fated polyanions may depend upon the number, orienta-
tion, and polymeric arrangement of sulfate groups. Sialic
acid containing gangliosides, when incorporated into lipo-
somes, inhibit the alternative complement pathway. More
than 90% of this inhibitory activity is lost after removal of
the terminal C9 carbon from the polyhydroxylated tail of
sialic acid or conversion of its carboxyl group to a hy-
droxymethyl group (68). When incorporated into liposomal
membranes, the monoganglioside GM1 and sialosylpara-
globoside inhibit activation of the alternative pathway of
complement, an effect that is reversed by neuraminidase
treatment. Increased binding of radiolabeled fH to lipo-
some-bound C3b has been observed in the presence of
GM1 (69). Polyanion binding regions on fH have been
previously defined using heparin (7, 9, 10). The first hep-
arin binding site on fH was identified as a positively
charged arginine-rich site in SCR 13 (9). Subsequently, us-
ing the same rH mutant molecules that we have used in
this study, a second higher-affinity binding site was identi-
fied between SCRs 6 and 10 (7). Another recent study
(10), using fH SCR deletion mutant proteins expressed in
Chinese hamster ovary cells, identified a heparin binding
domain in SCR 7. The possibility that additional heparin
binding sites (other than SCR 13) exist within SCRs 10–
20 was raised in that study because a double deletion of
SCRs 7 and 13 from the full-length fH showed .97%
binding to heparin-agarose and an elution profile similar to
that of a single deletion of SCR 7.
Deletion mutations of complement regulatory proteins
organized in SCR domains have been used in other studies
to define binding regions of fH and other complement reg-
ulatory proteins (7, 70–73). This approach is justifiable be-
cause of the apparent independent folding of the 20 do-
mains of fH and their linear arrangement. Using rH mutant
proteins that were expressed in the baculovirus system, we
have identified SCRs 16–20 as containing a novel sialic
acid binding site on fH. Four rH mutant molecules (rHD5,
rHD13, rHD1-5, and rHD11-15) showed greater binding
than did rH. This phenomenon has also been observed
with rHD1-5, rHD16-20, and rHD11-20 in a recent study
that used rH and six rH mutant molecules to identify SCRs
6–10 as the region in fH that bound to M protein of Strep-
tococcus pyogenes (72). The increased binding of certain rH
mutants compared to rH may be due to differences in size
and/or charge of the mutant molecules. Sialic acid, when
configured onto gonococcal LOS, binds a region on fH not
Figure 7. Specificity of neuramini-
dase treatment of gonococcal LOS.
Samples used in flow cytometry (Fig. 6)
were centrifuged, and then the pellets
were harvested, digested, and subjected
to electrophoresis on a 15% SDS-poly-
acrylamide gel followed by Western
blotting. Blots were probed with mAb 3F11 that specifically recognizes
the sialylation epitope (Galb1®4GlcNAc) on LOS. Binding of 3F11 is
abolished when LOS is sialylated, and is restored with neuraminidase
treatment. Lane 1: 24-1 NANA incubated with fH alone; lane 2: empty;
lane 3: 24-1 NANA treated with neuraminidase before incubation with fH
(Neu®fH); lane 4: 24-1 NANA treated with neuraminidase after incu-
bation with fH (fH®Neu).749 Ram et al.
predicted by other in vitro experiments. Furthermore,
these results impart another biological function to the
COOH-terminal end (SCRs 16–20) of the fH molecule,
which previously was believed to contain only a C3b bind-
ing site (7). Binding of the COOH-terminal end of fH to
sialic acid on gonococcal LOS might enable the highly
elongated and flexible fH molecule (74) to interact effi-
ciently with nearby C3b molecules deposited on the bacte-
rium through the NH2-terminal cofactor activity-bearing
domains (SCRs 1–5) as well as through the second C3b-
binding region (SCRs 6–10).
We confirmed that sialic acid was the receptor for fH by
neuraminidase treatment both before and after incubation
of the bacteria with fH. In both instances the ability to bind
fH was lost, suggesting that in this system sialic acid is es-
sential for the binding of fH. If a second receptor had been
involved in binding fH, residual fH should have been detected
when incubation with fH was followed by neuraminidase
treatment. In our experiments using sialylated organisms,
all of the bound fH was associated with sialic acid. This is
the first unequivocal demonstration of fH binding to sialic
acid on a microbial surface.
Sialylation of neisserial LOS can contribute to pathoge-
nicity in several other ways. These include decreased phago-
cytosis of gonococci or meningococci by human neutro-
phils (75–78), decreased ability to bind IgM and IgA (59),
and decreased ability to stimulate an oxidative burst in neu-
trophils and to adhere to neutrophils in the absence of
complement and antibody (78).
In this study we have defined the mechanism of serum
resistance of sialylated gonococci. However, other gono-
coccal strains (predominantly isolated from patients with
disseminated gonococcal infection) remain SR in in vitro
assays (termed stable serum resistance) without the addition
of CMP-NANA (79–81). Using flow cytometry, we have
shown that most of these stable SR strains also bind signifi-
cant amounts of fH (our unpublished data), suggesting that
another acceptor site(s) for fH may also exist.
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